| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8458525 | Pathology - Research and Practice | 2017 | 23 Pages |
Abstract
Our clinicopathological data are in keeping with previous studies; in most cases, MASC is a low-grade malignancy with overall favorable prognosis. In rare cases, however, MASC with high-grade transformation may behave aggressively, and these patients could benefit from targeted biological treatment using tyrosine kinase inhibitors.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
F. Baghai, F. Yazdani, A. Etebarian, A. Garajei, A. Skalova,